Thomas Damgaard Sandahl

Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. / Laursen, Tea Lund; Wong, Grace Lai-Hung; Kazankov, Konstantin et al.

In: Journal of Gastroenterology and Hepatology, Vol. 3, No. 2, 2018, p. 484–491.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Laursen, Tea Lund ; Wong, Grace Lai-Hung ; Kazankov, Konstantin et al. / Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. In: Journal of Gastroenterology and Hepatology. 2018 ; Vol. 3, No. 2. pp. 484–491.

Bibtex

@article{f8c6325c1b814bceb46b178f8fd9a97c,
title = "Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment",
abstract = "BACKGROUND AND AIM: Liver macrophages are activated in chronic hepatitis B virus (CHB) infection and play a pivotal role in hepatic inflammation and fibrosis. However, their role during anti-viral treatment is unclear. The soluble (s) macrophage activation markers, sCD163 and mannose receptor (sMR), are released during liver damage and their serum levels reflect liver disease severity and portal hypertension. We aimed to investigate associations between sCD163 and sMR and histopathological activity and fibrosis, and changes in sCD163, sMR and hepatic CD163-expression following anti-viral treatment in CHB patients.METHODS: We assessed Ishak histological necroinflammatory activity and fibrosis scores in liver biopsies from 254 CHB patients, and serially in 71 patients before and after nucleoside-analogue treatment. Liver CD163-expression was semi-quantitatively determined by immunohistochemistry and serum sCD163 and sMR measured by ELISA.RESULTS: Before treatment, the mean levels of sCD163 and sMR were 3.57 (SD 1.72) mg L(-1) and 0.35 (0.12) mg L(-1) . sCD163 and sMR increased with histological inflammatory activity (sCD163: r=0.46, p<0.00001; sMR: r=0.48, p<0.00001) and correlated positively with fibrosis (sCD163: OR 1.16, 95%CI:1.03-1.31; sMR: OR 1.34, 95%CI:1.13-1.59); both were markers of fibrosis independent of other biochemical parameters and risk factors. Anti-viral treatment significantly reduced sCD163 (3.76 (1.46) vs. 2.31 (0.95), p<0.00001), sMR (0.37 (0.1) vs. 0.29 (0.07), p<0.00001) and hepatic CD163-expression (p=0.0002).CONCLUSIONS: The macrophage activation markers sCD163 and sMR were associated with activity and fibrosis in liver biopsies from CHB patients. Both serum markers decreased with anti-viral treatment, along with decreased hepatic CD163 expression.",
keywords = "Journal Article",
author = "Laursen, {Tea Lund} and Wong, {Grace Lai-Hung} and Konstantin Kazankov and Thomas Sandahl and M{\o}ller, {Holger Jon} and Stephen Hamilton-Dutoit and Jacob George and Chan, {Henry Lik-Yuen} and Henning Gr{\o}nbaek",
note = "This article is protected by copyright. All rights reserved.",
year = "2018",
doi = "10.1111/jgh.13849",
language = "English",
volume = "3",
pages = "484–491",
journal = "Journal of Gastroenterology and Hepatology",
issn = "0815-9319",
publisher = "Wiley-Blackwell Publishing Asia",
number = "2",

}

RIS

TY - JOUR

T1 - Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment

AU - Laursen, Tea Lund

AU - Wong, Grace Lai-Hung

AU - Kazankov, Konstantin

AU - Sandahl, Thomas

AU - Møller, Holger Jon

AU - Hamilton-Dutoit, Stephen

AU - George, Jacob

AU - Chan, Henry Lik-Yuen

AU - Grønbaek, Henning

N1 - This article is protected by copyright. All rights reserved.

PY - 2018

Y1 - 2018

N2 - BACKGROUND AND AIM: Liver macrophages are activated in chronic hepatitis B virus (CHB) infection and play a pivotal role in hepatic inflammation and fibrosis. However, their role during anti-viral treatment is unclear. The soluble (s) macrophage activation markers, sCD163 and mannose receptor (sMR), are released during liver damage and their serum levels reflect liver disease severity and portal hypertension. We aimed to investigate associations between sCD163 and sMR and histopathological activity and fibrosis, and changes in sCD163, sMR and hepatic CD163-expression following anti-viral treatment in CHB patients.METHODS: We assessed Ishak histological necroinflammatory activity and fibrosis scores in liver biopsies from 254 CHB patients, and serially in 71 patients before and after nucleoside-analogue treatment. Liver CD163-expression was semi-quantitatively determined by immunohistochemistry and serum sCD163 and sMR measured by ELISA.RESULTS: Before treatment, the mean levels of sCD163 and sMR were 3.57 (SD 1.72) mg L(-1) and 0.35 (0.12) mg L(-1) . sCD163 and sMR increased with histological inflammatory activity (sCD163: r=0.46, p<0.00001; sMR: r=0.48, p<0.00001) and correlated positively with fibrosis (sCD163: OR 1.16, 95%CI:1.03-1.31; sMR: OR 1.34, 95%CI:1.13-1.59); both were markers of fibrosis independent of other biochemical parameters and risk factors. Anti-viral treatment significantly reduced sCD163 (3.76 (1.46) vs. 2.31 (0.95), p<0.00001), sMR (0.37 (0.1) vs. 0.29 (0.07), p<0.00001) and hepatic CD163-expression (p=0.0002).CONCLUSIONS: The macrophage activation markers sCD163 and sMR were associated with activity and fibrosis in liver biopsies from CHB patients. Both serum markers decreased with anti-viral treatment, along with decreased hepatic CD163 expression.

AB - BACKGROUND AND AIM: Liver macrophages are activated in chronic hepatitis B virus (CHB) infection and play a pivotal role in hepatic inflammation and fibrosis. However, their role during anti-viral treatment is unclear. The soluble (s) macrophage activation markers, sCD163 and mannose receptor (sMR), are released during liver damage and their serum levels reflect liver disease severity and portal hypertension. We aimed to investigate associations between sCD163 and sMR and histopathological activity and fibrosis, and changes in sCD163, sMR and hepatic CD163-expression following anti-viral treatment in CHB patients.METHODS: We assessed Ishak histological necroinflammatory activity and fibrosis scores in liver biopsies from 254 CHB patients, and serially in 71 patients before and after nucleoside-analogue treatment. Liver CD163-expression was semi-quantitatively determined by immunohistochemistry and serum sCD163 and sMR measured by ELISA.RESULTS: Before treatment, the mean levels of sCD163 and sMR were 3.57 (SD 1.72) mg L(-1) and 0.35 (0.12) mg L(-1) . sCD163 and sMR increased with histological inflammatory activity (sCD163: r=0.46, p<0.00001; sMR: r=0.48, p<0.00001) and correlated positively with fibrosis (sCD163: OR 1.16, 95%CI:1.03-1.31; sMR: OR 1.34, 95%CI:1.13-1.59); both were markers of fibrosis independent of other biochemical parameters and risk factors. Anti-viral treatment significantly reduced sCD163 (3.76 (1.46) vs. 2.31 (0.95), p<0.00001), sMR (0.37 (0.1) vs. 0.29 (0.07), p<0.00001) and hepatic CD163-expression (p=0.0002).CONCLUSIONS: The macrophage activation markers sCD163 and sMR were associated with activity and fibrosis in liver biopsies from CHB patients. Both serum markers decreased with anti-viral treatment, along with decreased hepatic CD163 expression.

KW - Journal Article

U2 - 10.1111/jgh.13849

DO - 10.1111/jgh.13849

M3 - Journal article

C2 - 28618015

VL - 3

SP - 484

EP - 491

JO - Journal of Gastroenterology and Hepatology

JF - Journal of Gastroenterology and Hepatology

SN - 0815-9319

IS - 2

ER -